Cargando…
Apatinib as maintenance therapy in extensive-stage small-cell lung cancer: results from a single-center retrospective study
PURPOSE: To evaluate the efficacy of maintenance apatinib after chemotherapy for extensive-stage (ED) small-cell lung cancer (SCLC). PATIENTS AND METHODS: This was a retrospective analysis of 23 cases of extensive-stage SCLC admitted to the Affiliated Cancer Hospital of Zhengzhou University from Jan...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6326003/ https://www.ncbi.nlm.nih.gov/pubmed/30293117 http://dx.doi.org/10.1007/s00432-018-2764-8 |
_version_ | 1783386225815584768 |
---|---|
author | Yan, Xiangtao Wang, Qiming Wang, Huijuan Li, Peng Zhang, Guowei Zhang, Mina Zheng, Xuanxuan Yang, Jinpo Zhang, Xiaojuan Ma, Zhiyong |
author_facet | Yan, Xiangtao Wang, Qiming Wang, Huijuan Li, Peng Zhang, Guowei Zhang, Mina Zheng, Xuanxuan Yang, Jinpo Zhang, Xiaojuan Ma, Zhiyong |
author_sort | Yan, Xiangtao |
collection | PubMed |
description | PURPOSE: To evaluate the efficacy of maintenance apatinib after chemotherapy for extensive-stage (ED) small-cell lung cancer (SCLC). PATIENTS AND METHODS: This was a retrospective analysis of 23 cases of extensive-stage SCLC admitted to the Affiliated Cancer Hospital of Zhengzhou University from January 2015 to December 2017. The patients without progression after induction chemotherapy received apatinib 250 mg per day until disease progression or unacceptable toxicity occurred. We analyzed the median progression-free survival (PFS), median overall survival (OS) and safety. RESULTS: Of 23 enrolled patients, 1 was lost to follow-up. The median PFS from the time of maintenance therapy was 4.1 months (95% CI 3.63–4.57 months). The median PFS from the time of induction chemotherapy was 8.3 months (95% CI 7.20–9.40 months). The median OS from the time of maintenance therapy was 12.5 months (95% CI 5.51–19.49 months). The median OS from the time of induction chemotherapy was 17.0 months (95% CI 9.86–24.14 months). The most frequent treatment-related adverse events were hand–foot syndrome (43.5%, 10/23) and secondary hypertension (30.4%, 7/23), followed by fatigue, proteinuria, nausea, and oral mucositis (17.4%, 13.0%, 13.0%, and 8.7%, respectively). Hematologic toxicity included thrombocytopenia (30.4%), leucopenia (26.1%), and anemia (17.4%). The main grade 3 or 4 toxicities were hand–foot syndrome (8.7%, 2/23) and hypertension (4.3%, 1/23). CONCLUSION: Maintenance apatinib was safe and achieved encouraging PFS and OS in extensive-stage SCLC. |
format | Online Article Text |
id | pubmed-6326003 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-63260032019-01-23 Apatinib as maintenance therapy in extensive-stage small-cell lung cancer: results from a single-center retrospective study Yan, Xiangtao Wang, Qiming Wang, Huijuan Li, Peng Zhang, Guowei Zhang, Mina Zheng, Xuanxuan Yang, Jinpo Zhang, Xiaojuan Ma, Zhiyong J Cancer Res Clin Oncol Original Article – Clinical Oncology PURPOSE: To evaluate the efficacy of maintenance apatinib after chemotherapy for extensive-stage (ED) small-cell lung cancer (SCLC). PATIENTS AND METHODS: This was a retrospective analysis of 23 cases of extensive-stage SCLC admitted to the Affiliated Cancer Hospital of Zhengzhou University from January 2015 to December 2017. The patients without progression after induction chemotherapy received apatinib 250 mg per day until disease progression or unacceptable toxicity occurred. We analyzed the median progression-free survival (PFS), median overall survival (OS) and safety. RESULTS: Of 23 enrolled patients, 1 was lost to follow-up. The median PFS from the time of maintenance therapy was 4.1 months (95% CI 3.63–4.57 months). The median PFS from the time of induction chemotherapy was 8.3 months (95% CI 7.20–9.40 months). The median OS from the time of maintenance therapy was 12.5 months (95% CI 5.51–19.49 months). The median OS from the time of induction chemotherapy was 17.0 months (95% CI 9.86–24.14 months). The most frequent treatment-related adverse events were hand–foot syndrome (43.5%, 10/23) and secondary hypertension (30.4%, 7/23), followed by fatigue, proteinuria, nausea, and oral mucositis (17.4%, 13.0%, 13.0%, and 8.7%, respectively). Hematologic toxicity included thrombocytopenia (30.4%), leucopenia (26.1%), and anemia (17.4%). The main grade 3 or 4 toxicities were hand–foot syndrome (8.7%, 2/23) and hypertension (4.3%, 1/23). CONCLUSION: Maintenance apatinib was safe and achieved encouraging PFS and OS in extensive-stage SCLC. Springer Berlin Heidelberg 2018-10-06 2019 /pmc/articles/PMC6326003/ /pubmed/30293117 http://dx.doi.org/10.1007/s00432-018-2764-8 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Article – Clinical Oncology Yan, Xiangtao Wang, Qiming Wang, Huijuan Li, Peng Zhang, Guowei Zhang, Mina Zheng, Xuanxuan Yang, Jinpo Zhang, Xiaojuan Ma, Zhiyong Apatinib as maintenance therapy in extensive-stage small-cell lung cancer: results from a single-center retrospective study |
title | Apatinib as maintenance therapy in extensive-stage small-cell lung cancer: results from a single-center retrospective study |
title_full | Apatinib as maintenance therapy in extensive-stage small-cell lung cancer: results from a single-center retrospective study |
title_fullStr | Apatinib as maintenance therapy in extensive-stage small-cell lung cancer: results from a single-center retrospective study |
title_full_unstemmed | Apatinib as maintenance therapy in extensive-stage small-cell lung cancer: results from a single-center retrospective study |
title_short | Apatinib as maintenance therapy in extensive-stage small-cell lung cancer: results from a single-center retrospective study |
title_sort | apatinib as maintenance therapy in extensive-stage small-cell lung cancer: results from a single-center retrospective study |
topic | Original Article – Clinical Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6326003/ https://www.ncbi.nlm.nih.gov/pubmed/30293117 http://dx.doi.org/10.1007/s00432-018-2764-8 |
work_keys_str_mv | AT yanxiangtao apatinibasmaintenancetherapyinextensivestagesmallcelllungcancerresultsfromasinglecenterretrospectivestudy AT wangqiming apatinibasmaintenancetherapyinextensivestagesmallcelllungcancerresultsfromasinglecenterretrospectivestudy AT wanghuijuan apatinibasmaintenancetherapyinextensivestagesmallcelllungcancerresultsfromasinglecenterretrospectivestudy AT lipeng apatinibasmaintenancetherapyinextensivestagesmallcelllungcancerresultsfromasinglecenterretrospectivestudy AT zhangguowei apatinibasmaintenancetherapyinextensivestagesmallcelllungcancerresultsfromasinglecenterretrospectivestudy AT zhangmina apatinibasmaintenancetherapyinextensivestagesmallcelllungcancerresultsfromasinglecenterretrospectivestudy AT zhengxuanxuan apatinibasmaintenancetherapyinextensivestagesmallcelllungcancerresultsfromasinglecenterretrospectivestudy AT yangjinpo apatinibasmaintenancetherapyinextensivestagesmallcelllungcancerresultsfromasinglecenterretrospectivestudy AT zhangxiaojuan apatinibasmaintenancetherapyinextensivestagesmallcelllungcancerresultsfromasinglecenterretrospectivestudy AT mazhiyong apatinibasmaintenancetherapyinextensivestagesmallcelllungcancerresultsfromasinglecenterretrospectivestudy |